Cis-regulatory and long noncoding RNA alterations in breast cancer - current insights, biomarker utility, and the critical need for functional validation.

Abstract excerpt

Breast cancer's global prevalence underscores a critical need for novel biomarkers to guide treatment and improve patient outcomes. Biomarker discovery historically focused on mutations in protein coding regions, comprising merely 1% of the genome. However, with advances in whole-genome sequencing, the functional significance of the noncoding genome-comprising the remaining 99%-has become increasingly evident....

Topics

Join the communities discussing this publication.

• Biomarkers, Tumor
• Breast Neoplasms
• Gene Expression Regulation, Neoplastic
• MDM2 gene
• Mutation